World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
44
Citations
5864
World Ranking
4808
National Ranking
2157

Andrew Wiznia publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Andrew Wiznia sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 163 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Andrew Wiznia D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Wiznia sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 44 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Andrew Wiznia is affiliated with the Albert Einstein College of Medicine in the United States and has a research focus primarily within the field of medicine, with an emphasis on infectious diseases. Their scholarly contributions span various aspects of epidemiology, virology, and public health, including environmental and occupational health.

Their research extensively covers topics related to HIV/AIDS drug development and treatment, interventions in HIV/AIDS, and broader HIV research and treatment strategies. Additional topics include adolescent sexual and reproductive health, maternal mental health during pregnancy and postpartum, HIV-related health complications and treatments, and the detection and treatment of Pneumocystis jirovecii pneumonia.

The frequent coauthors collaborating with Andrew Wiznia include:

  • Reuben N. Robbins
  • Elaine J. Abrams
  • Claude A. Mellins
  • Curtis Dolezal
  • Luke Kluisza

Their work has been published repeatedly in several venues notable within the infectious diseases and HIV research communities, such as:

  • AIDS
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
  • AIDS and Behavior
  • Open Forum Infectious Diseases
  • SSRN Electronic Journal

Key publications by Andrew Wiznia include:

  • Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial (2023) - The Lancet HIV
  • Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children (2020) - The Journal of Infectious Diseases
  • Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study (2021) - Antimicrobial Agents and Chemotherapy
  • Risk Factors for Perinatal Transmission of Hepatitis C Virus (2023) - Obstetrics and Gynecology
  • Psychiatric trajectories across adolescence in perinatally HIV-exposed youth: the role of HIV infection and associations with viral load (2020) - AIDS

Best Publications

  • Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

    Russell B. Van Dyke;Sophia Lee;George M. Johnson;Andrew Wiznia

  • Pediatric Asthma: A Global Epidemic.

    Denise Serebrisky;Andrew Wiznia

  • A behavioral and cognitive profile of clinically stable HIV-infected children.

    Molly L. Nozyce;Sophia S. Lee;Andrew Wiznia;Sharon Nachman

  • Rates and Types of Psychiatric Disorders in Perinatally Human Immunodeficiency Virus-Infected Youth and Seroreverters

    Claude Ann Mellins;Elizabeth Brackis-Cott;Cheng-Shiun Leu;Katherine S. Elkington

  • Selective Loss of Innate CD4+ Vα24 Natural Killer T Cells in Human Immunodeficiency Virus Infection

    Johan K. Sandberg;Noam M. Fast;Emil H. Palacios;Glenn Fennelly

  • Human T-Cell Lymphotropic Virus Type III (HTLV-III) Embryopathy: A New Dysmorphic Syndrome Associated With Intrauterine HTLV-III Infection

    Robert W. Marion;Andrew A. Wiznia;R. Gordon Hutcheon;Arye Rubinstein

  • Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children - A randomized controlled trial

    Sharon A. Nachman;Kenneth Stanley;Ram Yogev;Stephen Pelton

  • The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy

    Russell B. Van Dyke;Bette T. Korber;Edwina Popek;Catherine Macken

  • A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection

    Ross E. McKinney;George M. Johnson;Kenneth Stanley;Florence H. Yong

  • Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.

    Rita J. Jeremy;Soyeon Kim;Molly Nozyce;Sharon Nachman

  • CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children

    Akihiko Saitoh;Elizabeth Sarles;Edmund Capparelli;Francesca Aweeka

  • Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth

    Claude A. Mellins;Katherine S. Elkington;Cheng-Shiun Leu;E. Karina Santamaria

  • Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate

    Paul Krogstad;Andrew Wiznia;Katherine Luzuriaga;Wayne Dankner

  • Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

    Sharon A. Nachman;Jane C. Lindsey;Jack Moye;Kenneth E. Stanley

  • Missed Opportunities for Perinatal HIV Prevention Among HIV-Exposed Infants Born 1996–2000, Pediatric Spectrum of HIV Disease Cohort

    Vicki Peters;Kai Lih Liu;Kenneth Dominguez;Toni Frederick

  • Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.

    Stephen M. Arpadi;Lauri E. Markowitz;Andrew L. Baughman;Kiran Shah

  • Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children : Week 24 results of a randomized controlled trial-PACTG 377

    A. Wiznia;K. Stanley;P. Krogstad;George M. Johnson

  • Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant.

    Cara C. Wilson;R. Clark Brown;Bette T. Korber;Barbara M. Wilkes

  • Duration of ruptured membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies

    M. B. Bulterys;M. G. Fowler;I. C. Hanson;M. Lemay

  • Natural Killer Cells in Perinatally HIV-1-Infected Children Exhibit Less Degranulation Compared to HIV-1-Exposed Uninfected Children and Their Expression of KIR2DL3, NKG2C, and NKp46 Correlates with Disease Severity

    Wassim M. Ballan;Bien-Aimee N. Vu;Brian R. Long;Christopher P. Loo

  • A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

    Ulrik B. Dragsted;Jan Gerstoft;Mike Youle;Zoe Fox

  • HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment.

    Johan K. Sandberg;Noam M. Fast;Kimberly A. Jordan;Scott N. Furlan

  • Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women.

    Joseph P. Mcgowan;Marilyn Crane;Andrew A. Wiznia;Steve Blum

  • Sexual and Drug Use Behavior in Perinatally HIV-Infected Youth: Mental Health and Family Influences

    Claude A. Mellins;Katherine S. Elkington;Jose A. Bauermeister;Elizabeth Brackis-Cott

  • Baseline Resistance to Nucleoside Reverse Transcriptase Inhibitors Fails to Predict Virologic Response to Combination Therapy in Children (PACTG 338)

    Susan A Fiscus;Andrea Kovacs;Leslie A Petch;Chengcheng Hu

  • Nucleoside Analogs Plus Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children

    Sharon A. Nachman;Kenneth Stanley;Ram Yogev;Stephen Pelton

Frequent Co-Authors

Sharon Nachman
Sharon Nachman Stony Brook Medicine
Ram Yogev
Ram Yogev Northwestern University
Douglas F. Nixon
Douglas F. Nixon Cornell University
Elaine J. Abrams
Elaine J. Abrams Columbia University
Edward P. Acosta
Edward P. Acosta University of Alabama at Birmingham
Claude A. Mellins
Claude A. Mellins Columbia University
Arye Rubinstein
Arye Rubinstein Albert Einstein College of Medicine
Stephen A. Spector
Stephen A. Spector University of California, San Diego
Curtis Dolezal
Curtis Dolezal Columbia University
Kenneth McIntosh
Kenneth McIntosh Boston Children's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career prospects. Nursing specializations such as psychiatric mental health offer targeted expertise. Students seeking flexible education options may find the cheapest pmhnp programs online ideal for advancing their clinical skills without financial strain.

Nurses often aim to elevate their roles by pursuing advanced practice degrees. Understanding the dnp salary by state can help aspiring practitioners make informed decisions about where to study and work, aligning their education with income potential.

For those already certified as Family Nurse Practitioners, there is the opportunity to specialize further. Programs that facilitate the fnp to acute care certification transition allow nurses to expand their clinical competencies and improve patient outcomes in more critical settings.

Accelerated pathways are also available for driven students. The accelerated fnp programs provide faster routes to certification, helping candidates quickly enter the workforce while maintaining high educational standards.

Best Scientists Citing Andrew Wiznia

Trending Scientists

Recently Published Articles